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Perspective: A Need for Better Maps of Disease 
The revolution in health care that was anticipated 
by the sequencing of the human genome has failed to 
materialize1. The failure rate for drugs in clinical 
development is still startlingly high despite 
unprecedented investment in R&D that reached a 
record $65 billion in 2009. This is largely due to the 
very high attrition rate for compounds in clinical 
development due to lack of efficacy in phase II trials: 
the success rate for progression of compounds from 
first-in-man studies to approved drug is only 11%2. 
This represents a failure of biology in selecting the 
correct target rather than a failure of chemistry; many 
compounds are shown to be safe and to engage the 
intended target but do not improve the primary 
indication. This failure stems from the simplistic ways 
in which we have historically studied potential drug 
targets for complex diseases and indicates a need for 
more innovative approaches to identify causal 
relationships between molecular entities and disease. 
Biology is rapidly changing and becoming a 
technology and data-intensive science with the 
development of new instrumentation to measure 
various molecular states in greater detail. Herein lays 
an opportunity to transform our understanding of the 
molecular underpinnings of disease and develop 
modeling frameworks that can describe complex 
systems and predict their behavior. Without these 
models acting as maps, biologists risk drowning in an 
ever-growing sea of data. This vision for biology, to 
use large-scale data to model disease, reflects parallel 
developments in other scientific disciplines: for 
example, modeling future trends in climate based on 
complex meteorological information in atmospheric 
science. The term fourth paradigm has been coined for 
this “data intensive” science discovery to distinguish it  
 
from empiric, theoretical and computational 
approaches3. 
While the physical sciences have been dominated 
by deductive modeling approaches, these techniques 
have had a more scattered impact across biology4. 
Molecular dynamic simulation of protein structures and 
physiological systems models provide areas where 
biological systems can be well described using 
deductive models and validated using experimental 
data. However, when confronted by the enormous 
complexity and general lack of specific knowledge in 
biological systems these models are often too under-
constrained to be applied. In these cases, methods 
based on statistical inference are an alternative way to 
identify key molecular relationships linked to disease 
phenotypes. A number of successes using this 
approach have been reported in the past several 
years5-13. At one level simple pair-wise analysis of 
alterations in human diseases, be it from DNA to 
phenotype in genome-wide association studies or from 
mRNA to phenotype in gene expression profiling 
studies, may be useful in providing essential lists of 
altered components. However, to uncover the 
essential mechanistic relationships between molecular 
changes and disease more integrative modeling 
methods that combine multiple complex molecular 
traits with phenotypic outcomes will be required14,15. In 
the long-term, different modeling approaches will likely 
be necessary to deliver complete, detailed and 
accurate models that can predict the behavior of 
biological systems. The particular approach will be 
linked to the question being addressed such that 
problems of classification - for disease outcome, drug 
response, etc – may require different models from 
those directed at understanding mechanisms and 
predicting therapeutic intervention points. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
88
3.
1 
: P
os
te
d 
4 
Ap
r 2
01
1
Sage Bionetworks Commons and Platform 
 
         
Page 2 
Building a Commons as a Means to Develop Better 
Maps of Disease 
The challenge of generating predictive molecular 
maps of disease is large and complex and is not likely 
to be solved by any one group. Instead, it will be 
necessary for biology to adopt the community-based 
practices that have proven successful in other areas of 
science and technology. At their core these efforts 
involve the open release of data for broad access. A 
good example for this comes from the Earth Sciences. 
The National Center for Atmospheric Research 
(NCAR) provides a "Community Data Portal" to over 
8,000 datasets relevant to the atmosphere, the Earth 
system and the Sun16. In addition, it provides tools for 
the analysis of this data and hosts community 
developed models thereby providing national and 
regional decision-makers with the most advanced 
science in weather and climate modeling. Science can 
also learn from the commercial world how broad 
sharing of data can drive improvements in 
models: Netflix has been able to improve its movie 
recommendation engine by creating a public challenge 
seeded with data describing user ratings of movies17. 
In both cases, the release of large, well-curated 
datasets into the public domain has driven significant 
improvements in modeling techniques. Movements to 
similarly share data relevant for research into human 
disease mechanisms are beginning to gain broad 
attention18-22. 
To make data truly easy to use, and also to enable 
scientists to reproduce and build on the work of others, 
it is not simply enough to deposit it into the public 
domain. It is also necessary to curate and document 
the data as well as the methods, tools and workflows 
used in analysis. Once again, biology would do well to 
learn from examples in other disciplines, such as the 
open source software industry where successful 
projects provide not just accessible code, but also 
invest effort in supporting documentation and 
developer tools that help new engineers build on 
previous work. Biology has traditionally operated as a 
“single use science” in which the results of one group 
are not readily available to be built upon by others 
because of issues around access to data and methods 
and inadequate documentation of what was actually 
done. Despite efforts by funding agencies and 
publishers, data sharing is still intermittent and data 
that are made accessible are often done so in a 
fashion that does not provide sufficient information for 
data re-use. In part this stems from the current lack of 
a suitable mechanism for ensuring reproducibility, with 
print journals being a poor avenue for hosting large 
datasets and complex algorithms23. Without provision 
of sufficient methodological detail, the results of 
modeling analyses are not of use to the community 
and do not advance biological understanding24. Indeed 
why should it be possible to publish in high profile 
journals if other scientists cannot reproduce the 
analyses of the authors let alone build upon the 
results? As previously stated “an article about a 
computational result is advertising, not scholarship. 
The actual scholarship is the full software 
environment, code and data that produced the 
result”25. 
The concept of a “Commons” in which contributor 
scientists can collaborate together in transparent and 
structured ways to build better maps of disease from a 
common reference of curated data is central to an 
effort being driven by Sage Bionetworks. The goal is to 
develop an innovation space where scientists can 
compute and collaborate on various clinical and 
genomic data, use tools to build models of human 
disease and modify those built by others. In this vision, 
contributors are not simply people who upload or 
download data for isolated use as for conventional 
database efforts. Instead contributors are active 
participants that build collective content in a manner 
analogous to other distributed community projects 
such as Wikipedia. This uncouples the data generators 
from the data analyzers, effectively crowdsources the 
evolution of disease models, and provides an 
accelerated mechanism for the dissemination of 
knowledge.  
Community involvement will be necessary to 
address the many concerns such a complex project 
will encounter, including ways to incentivize data 
sharing, attribution for data generators and map 
builders, and policy issues associated with human 
data protection. Engagement of stakeholders across 
different constituencies to drive the development of the 
policies and resources for the project has been 
important from the beginning and continues to be so26. 
In this commentary we will describe important aspects 
of the project including the efforts to date in building a 
platform and data and network model repository and 
the associated tools, the development of data-sharing 
rules and policies, and how this will drive us towards 
better maps of disease and a forum for reproducible 
and re-usable data and analyses. 
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The Sage Bionetworks Platform 
Sage Bionetworks is a non-profit organization with 
a mission to create a Commons where integrative 
bionetworks evolved by contributor scientists 
accelerate the elimination of human disease 
(www.sagebase.org). Central to the Commons is the 
Sage Bionetworks Platform: a resource to provide 
broad access to molecular network models of disease, 
and the underlying datasets and algorithms used to 
construct them. For clarity throughout this commentary 
we will refer to the “Platform” as representing the 
infrastructure being developed to enable community-
based genomic analysis. This includes the data and 
network repository, the IT infrastructure in which data 
are housed and accessed by users, and the tools that 
allow manipulation and analysis of the data (Figure 1). 
 
IT Infrastructure: The Platform provides a number of 
functionalities: management of datasets, analysis 
code, and network models; a workflow and versioning 
system that can track the specific dataset and code 
that was used for a particular analysis; and a suite of 
tools to enable scientific analysis and collaboration 
(Figure 1). Datasets may be hosted by the Platform or 
linked to when the data generator or other groups 
hosting the data have imposed restrictions on its 
redistribution (e.g. dbGAP or TCGA). In cases where 
redistribution of data is not allowed the Platform will 
reference the data source and provide code necessary 
to process the data into a standard format once the 
user has received the data directly from the data 
source. Regardless of physical location, the federated 
collection of curated, adjusted, and analyzed datasets, 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Sage Bionetworks Platform Architecture: The Platform Interface uses a set of web services to provide access to 
the Data Repository: a federated collection of curated, adjusted, and analyzed datasets, network models, and code. The 
Platform may also reference restricted data stored in external databases such as dbGAP or TCGA. In these cases, rather than 
providing data the Platform will provide a link to the data source and code necessary to process and curate the data into a 
standard format; the user can then apply this code to the data once they have received the necessary permissions through the 
established application processes from these external databases. All resources managed by the Platform can be referenced 
as objects via a URL following linked data principles. This approach allows storage of data and metadata using persistence 
mechanisms appropriate for each data modality, while abstracting multiple clients away from the details of how data and 
services are obtained. Integration with ontology services and support for a rich query language would occur on the Platform 
back-end, allowing multiple clients (e.g., R and the web client) to run similar queries across hosted data. Versioning of data, 
workflows, and tools allows the details of how individual network models are generated to be documented and hence 
reproduced. Storage of the data repository and services in the cloud allows for scalability, access, and the potential to use high 
performance compute facilities directly from the platform. 
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network models, and code constitutes a repository that 
scientists may access and reuse in new projects. 
A set of applications will support various types of 
users, data curators and bioinformaticians to 
biologists, similar to open source development 
environments.  A web portal under development will 
allow researchers to search and navigate through 
content relevant to their research interests and form 
projects with existing or new colleagues.  General-
purpose tools like wikis, user forums, and issue 
trackers can easily be adopted from other domains to 
support scientific research teams.  More focused 
analytical work and scientific visualizations will be 
supported by integrating existing tools with platform 
services to provide access to hosted data in an 
environment already known and comfortable to 
analysts. For example, we have begun the 
development of an R package to allow platform-hosted 
data to be accessed in this open-source environment, 
and link to the wealth of existing analysis methodology 
available via resources like Bioconductor. 
Access to shared data and functionality across 
applications are provided by a set of web services that 
provide a central location for a variety of features 
including annotation, indexing, history tracking, 
versioning, authentication/authorization, and data 
persistence. We have designed an application 
programming interface (API) that allows for structured 
queries including filtering, sorting and paging, across 
the metadata of all datasets, network models, and 
tools registered by the Platform.  The API, inspired by 
Facebook’s Graph API and Query Language and 
API27, consists of both a set of simple calls to access 
individual datasets, plus a richer query against the 
metadata store. Structured query services can be 
semantically enhanced by having the Platform 
services delegate to external services, such as 
NCBO28, to expand query terms prior to interrogating 
the internal persistence layer, e.g., to find datasets 
where the tissue is labeled as “Cerebrum” or 
“Cerebellum”.  A service-oriented architecture also has 
the advantage of helping to keep analysis code near 
the data, which is becoming ever more problematic to 
move as data volumes are growing faster than network 
bandwidth. Due to the scope of the data and analysis 
demands, the platform will be built to take advantage 
of the maturing set of cloud compute technologies that 
can provide scientists super-compute power on 
demand without the up-front capital costs of building 
and managing a private cluster. 
Data and Network Repository: The data content 
underlying the Platform is stored in a centralized 
repository of curated data and network models 
(http://www.sagebase.org/commons/repository.php 
and Figure 2). The process of curation of acquired 
data involves both data integrity checks and 
transformation of the dataset into a standard format as 
described below. These curated datasets represent an 
essential building block for shared, versioned 
analyses. The platform will also provide a second 
“analysis-ready” version of each dataset that has been 
through a Quality Control (QC) process in preparation 
for modeling in conjunction with tools, source code and 
detailed documentation that link the adjusted dataset 
to the underlying curated dataset (Figure 2). We 
recognize that normalization and data adjustment 
processes may differ depending on analytical goals 
and so this effort will provide a mechanism for end 
users to create and store different versions of each 
dataset that include code written for alternative 
adjustment strategies. We welcome input from the 
community and contributions of raw, curated and/or 
adjusted datasets in conjunction with the relevant 
annotation and/or analysis tools.  
Initial efforts to populate the Platform have 
focused on the collection and curation of multi-layered 
genomic datasets that are essential for the 
development of predictive computational models. Data 
are collected from diverse sources (Figure 2); from 
studies in public repositories as well as directly from 
investigators employed in either academic or 
commercial efforts. Although this project is not aimed 
at recreating the extensively populated genomic 
databases that already exist29-32, we are working to 
improve the usability of publicly available datasets that 
are best suited for model building. Much of the data 
currently available through public repositories lacks 
critical information required for effective use; datasets 
may lack essential metadata or annotations, unique 
participant identifiers that map individuals across data-
types, or adequate descriptions of data processing. In 
addition, data are not typically shared in  a standard   
format,  requiring significant effort for analysts to 
curate them. Furthermore, model building is most 
effective when using data containing multiple-layers of 
genomic and phenotypic information (e.g., DNA 
variation, expression profiles, and clinical traits) but 
these different types of data are often deposited 
across multiple repositories. For studies in non-human 
model systems, no repository exists.  
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
11
.5
88
3.
1 
: P
os
te
d 
4 
Ap
r 2
01
1
Sage Bionetworks Commons and Platform 
 
Page 5 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Process of Data Acquisition, Curation, Adjustment, and Modeling. Data flows into the repository from a number 
of different sources with examples listed. Individual datasets typically contain different data-types and are submitted in various 
formats. Curation involves reformatting into a common tab-delimited text matrix format. This curated standard format is 
available for download as well as allowing the development of workflows for common manipulations (e.g., adjustments for 
technical co-variates such as gene expression array batch). The “curated and adjusted” dataset is also available for download. 
Data analysts or modelers may use the curated data or the curated and adjusted data for downstream analyses; the important 
feature being that the version of the dataset that is used for an analysis as well as the code and workflows are stored. Allowing 
different types of users to interact with the data at different points has advantages. For example, providing tools to enable 
curation of a dataset into a standard format provides the user with the benefit of easy curation and opens up tools for 
downsteam QC and analysis. For the repository, the potential benefit in providing these tools may be in encouraging broader 
data sharing. 
Datasets in the Platform repository are generally 
derived from human or mammalian studies containing 
more than 50 subjects: mammalian models tend to 
more accurately reflect the complex interactions 
observed in human disease and modeling techniques 
require a minimum number of individuals in order to 
build accurate models. Select genomic datasets that 
contain phenotypic traits in conjunction with either 
DNA variation or molecular trait data can be used 
within a subset of modeling techniques and may be 
included. Currently, molecular traits and genotype data 
are most commonly available as genome-wide gene 
expression profiles and SNP profiles respectively, but 
in principle any comprehensive measures of molecular 
phenotypes can be considered as they become 
available, including proteomic, metabolomic, whole 
genome and transcriptome sequencing, miRNA, and 
other types of molecular data. We encourage 
investigators to directly contact Sage Bionetworks 
regarding datasets or models to be shared 
(repdata@sagebase.org). 
The curation of datasets involves a series of 
integrity checks and transformations into a standard 
format to maximize accessibility and utility. 
Specifically, the steps are: (1) collecting and 
inventorying the data; (2) verifying sample matching 
across data-types, including checking for 
inconsistencies in the data based on inferred gender 
and repeated samples; and (3) formatting of the data 
files to standard formats. To maximize flexibility, 
curated data is released in a basic tab-delimited format 
with each data-type stored in rectangular tab-delimited 
files, where individuals populate the columns and the 
molecular (SNP, gene expression reporter, etc) or 
clinical phenotypes populate the rows (Figure 3). Each 
data-type has a companion annotation file, which is 
also in tab-delimited format, where each row describes 
the molecular (probe, marker) or clinical (trait) 
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phenotypes present in the data file. Sample 
annotations, such as batch information, are stored in 
the phenotype file along with the traits measured on 
each individual. While this manner of data storage 
requires some manipulation to conform to each of the 
commonly used data formats for downstream analysis 
(e.g., Bioconductor, Matlab, Plink), the standard and 
flexible nature allows tools to be readily written to 
perform that manipulation. These tools will be 
distributed through the Platform, as well as through 
other standard tool-sharing mechanisms. 
Standardizing formats and annotations will facilitate 
data discovery and re-use. Ultimately we aim to create 
a set of semantically rich annotations for curated data 
and validate these using ontology services (e.g., as 
supplied by the NCBO)28,33 to ensure consistency of 
terminology across datasets. For clinical data, it will be 
necessary to also map clinical variables and 
covariates to ontologies in a similar fashion to facilitate 
meta-analysis across similar clinical studies. Curation 
also allows processes to be employed that aid in the 
protection of patient privacy34. A detailed description of 
the curation process and the resultant curated data 
packet including the content and format are available 
at the Sage Bionetworks website: 
http://sagebase.org/downloads/SageBio_DataSpecific
ation_MAR2011.pdf. 
The ultimate goal of this curation effort is to 
provide a mechanism for the collaborative generation, 
modification and improvement of predictive 
computational network models of disease. Networks 
are a convenient way to represent complex molecular 
interactions and to provide a framework for predicting 
causal relationships between molecular entities and 
clinical outcomes. However, the current standard of 
publishing modeling methods as general descriptions 
in manuscripts does not provide sufficient detail for a 
network to be accurately reproduced. Network models 
can be decomposed into a collection of triplets that 
define the relationship (or edge) between two nodes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Graphical Representation of a Curated Data Packet. All data (matrix files) and annotations (dictionary files) are 
contained in tab-delimited text files. Each data-type has a matrix file containing the data-type identifier on the rows and the 
individuals on the columns. Associated with each matrix file is a “dictionary” file that provides annotations for that particular 
data-type. In addition, there is an individual dictionary file that describes the individuals in the study. A free text metadata file 
that describes the study design, data generation technologies, data contributor, and terms of data use accompanies each data 
packet. The example shown is a “standard” Affymetrix package with gene expression data, genotype data, and phenotype 
data; note in the Affymetrix technology individual sequences designed to hybridize to specific RNA species are termed 
features. More complex datasets may contain additional data-types and accompanying dictionary files. 
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where a node represents either a molecular entity 
such as a gene or protein or a phenotype such as 
biochemical measures or clinical outcomes (Figure 4).  
 
Figure 4: Example of a Network Model. A graphical 
network model describes the relationships between 
molecular or phenotypic entities. Typically this is modeled in 
the form of nodes representing genes, proteins, or 
metabolites, and edges or connections, describing the 
relationships between them. Relationships can be the 
correlation of continuous variables across a population, 
physical protein interactions, or other such dependencies. 
The graphical structure can convey additional information 
such as directionality, strength of a connection, and/or the 
confidence in a connection. In the example the direction of 
information flow through the network, derived from causal 
inference, is denoted by arrows, such that node 1 drives the 
behavior of nodes 2 and 3. Note the lack of edge between 2 
and 3 indicates the effects of 1 on 2 and of 1 on 3 are 
independent of each other. The lack of arrows between 2 
and 4 and 2 and 5 indicates no directionality due to 
uncertainty of the causal relationships. The strength of 
connections can be shown in terms of the width of edges 
(compare 1 to 2 versus 1 to 3) and the confidence in the 
existence of an edge by numeric terms (compare 2 to 4 
versus 2 to 5). 
 
 
This information can be conveniently shared 
through text files. This model format, as with the 
curated data format, has been selected because it is a 
readily useable, universally exchangeable format and 
tools that transform models from this format into other 
common formats can be developed as necessary. 
Distribution through the Platform of models linked to 
underlying data, detailed and versioned code, and 
analytical workflows, will ensure that models are built 
in a reproducible manner. This transparency is 
designed to encourage collaboration on the decisions 
made within the modeling process, to ensure that the 
quality of network models can be meaningfully 
assessed, and to provide a forum for the development 
of modeling standards and the sharing of modeling 
techniques. Interactive feedback will further drive this 
process and direct biological researchers to high 
quality models from which they can inform their own 
research efforts. Initially we will ask model generators 
to provide the source code used to generate each 
model but ultimately the Platform will be able to 
incorporate standardized modeling tools and track the 
methods used by the modeler. In addition, we 
recognize that other analyses and representations of 
the data beyond networks are also useful and we 
anticipate that the Platform will also support these. 
 
Tool Repository: A key feature of the platform will be 
the tools developed both by Sage Bionetworks and by 
the broader scientific community for the manipulation 
and analysis of data (Figure 2). As an example, one of 
the significant bottlenecks in analysis of large-scale 
genomic data is the time and effort required to curate 
and QC the data. As an initial effort we aim to provide 
a standardized system for data curation with specific 
software tools to facilitate both the preparation of the 
basic curated data files and also their conversion to 
other data formats for downstream analysis. We 
envisage that this alone will be of significant value to 
the community; curation of data is often a time 
consuming and even daunting task for the less 
experienced investigator. Further, it has the potential 
to both incentivize data sharing and provide a 
mechanism for scaling the curation process by 
involving a broader group in the process. Additionally, 
tools for data adjustment and reformatting, as well as 
for model building, will be developed. These software 
tools (http://www.sagebase.org/research/tools.php) will 
be open source in the sense that the source code will 
be freely available under a license that not only allows, 
but also encourages, the sharing of the code and any 
enhancements made to it.  
   
Data Sharing and Reproducible Science  
In order to provide a community for collaboration, 
the data, tools and models shared through the 
Platform must be made broadly available with the 
fewest possible restrictions. It is essential that this 
resource be as accessible to a high school student 
developing a science project as to an academic 
investigator that specializes in modeling 
methodologies. For this reason, access to the Platform 
will be available to any registered user for research or 
training purposes. Users who want to download data 
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will be authenticated via a valid name and e-mail 
address and will be encouraged to provide a short 
paragraph outlining analytical goals the first time they 
request access to a dataset. The identity of 
researchers and the analytical plans for each dataset 
will be made available to the community but will not be 
used to determine eligibility for data access.  
Data sharing requires a willingness of data 
generators to provide access to data –something that 
is becoming more appreciated to maximize research 
impact and accelerate the rate of scientific discovery18-
22,35. Although the benefits of sharing scientific data 
are widely acknowledged, the implementation of this 
process has lagged due to multiple technical and 
cultural challenges. Responsibilities and funding for 
the organization, storage, and curation efforts, a 
prerequisite for widespread data sharing, remain 
unclear. For this reason, data are often shared in a 
manner that is difficult to interpret or that lacks 
essential elements required for the data to be reused. 
One major barrier to data sharing is the perception that 
data analysts get a broader benefit from sharing of 
data than do data generators or curators. A truly open 
policy towards the rapid and broad sharing of data will 
necessitate novel mechanisms that properly 
acknowledge the efforts that go into data generation 
and curation. This will include formally linking these 
efforts to the datasets, journal citations, and 
recognition of data generation and sharing efforts 
within professional merit systems including 
qualifications for tenure advancement. Some of the 
solutions to broader data sharing are already being 
driven by publishers and funders in policies requiring 
data deposition prior to manuscript publication and/or 
the completion of a funding cycle36-38. Other initiatives 
such as mechanisms for attributions beyond standard 
print publications are likely to be important39. 
Sharing of human genomic data presents 
additional challenges. Common concerns include 
maintenance of the privacy of human participants and 
minimization of the risk that misuse of the data could 
lead to stigmatization or discrimination in insurance, 
employment or other situations. Participant health 
information is protected both by federal laws40,41 and 
by state laws that can impose additional restrictions. In 
accordance with these rules all data available through 
the Platform will be stripped of identifiable 
information41. A number of efforts to change the 
patient consent process and allow patients to control 
how and with whom their data are shared are being 
discussed as a potential solution to guarantee an 
individual’s right to selective disclosure of their data42. 
Another approach is to engage the communities of 
users and contributors to act as stewards of the data. 
The notion of data stewardship implies mutual 
investments and shared responsibility by everyone to 
protect the interests of study participants as well as the 
interests of investigators. In this new paradigm, shared 
expectations and trust among community participants 
are essential43. A resource like the Sage Bionetworks 
Platform should be used to increase knowledge as a 
benefit to the community within the context of respect 
for the values and intentions of study participants and 
in a manner that limits risk for misuse leading to 
population discrimination and/or marginalization. To 
this end, Sage Bionetworks will require that users of 
the Platform agree to certain Terms of Use and ethical 
behaviors such as the promise not to identify human 
participants and the agreement not to use the data in a 
way that would enable genetic discrimination (see: 
http://sagebase.org/downloads/SageBio_TermsOfUse
_MAR2011.pdf). Data submitters may indicate 
additional terms and use restrictions to certain 
datasets in accordance with participant’s informed 
consent directives, or on datasets whose full 
disclosure could carry risks for individual’s privacy or 
group stigmatization.  These terms or restrictions may 
vary by study to provide the appropriate protection of 
participants in each trial, i.e., limitation to certain fields 
of study, location of research, and analysis types. 
Some genomic repositories and institutions (e.g., 
dbGAP, ICGC) have developed their own data access 
policies and procedures to prevent the unrestricted 
dissemination and potential misuse of human genomic 
data, and where appropriate we will direct users to 
apply for data access through the appropriate 
established mechanisms selected by the data 
contributor (e.g., dbGaP or institution websites). In 
these cases only the software code and network 
models derived from the data will be shared directly 
through the Platform with a reference to the underlying 
dataset.  Sage Bionetworks does not currently host 
restricted datasets but in the eventuality where 
restricted datasets are stored in the Platform, data 
users will be expected to fully comply with the 
limitations and restrictions set by the data submitter.  
Sage Bionetworks will not arbitrarily impose 
restrictions to data use. The consequences of violating 
these rules will be the denial of continued access to 
the Sage Bionetworks website 
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With greater openness comes the need for greater 
accountability and vigilance through community 
engagement. We propose to use a public forum to 
promote ethical behavior and prevent misuse of the 
data.  The Platform will provide a way to give feedback 
and log in concerns so that issues, whether logistic, 
scientific, ethical or regulatory can be brought to the 
attention of the community and be rectified promptly. 
This model promotes a different culture and requires 
new governance guidelines. We highlight how Sage 
Bionetworks proposes to address these issues and the 
challenges associated with broad sharing of genomic 
data at the Sage Bionetworks website (see: 
http://sagebase.org/downloads/SageBio_Governance_
MAR2011.pdf) 
 
Future Directions   
The Sage Commons and Platform is designed to 
confer broad benefits across the biomedical research 
community, both to researchers that employ these 
analytical processes to generate new network models 
and to researchers that want to use these models to 
inform their own work in disease biology. It is hoped 
that this environment will foster the development of 
more reliable models through iterative community 
improvements in analytical methodologies. Through 
the broader context of the Commons, the Platform will 
provide a mechanism to link model generators with 
researchers and clinicians that are poised to validate 
modeling hypotheses and incorporate modeling results 
into research directed at understanding physiological 
or disease states and therapeutic development efforts. 
We believe this effort distinguishes itself from the 
data warehouse-based efforts at NCBI, EBI, and 
elsewhere29-32 in going beyond the straight repository 
model to incorporate the concepts of community-
based analysis and modeling.  Other efforts to build 
model repositories, such as EBI's BioModel44, have 
focused on deductive methodologies and defining 
standards for representing mechanistic models of 
biochemical systems.  While we take inspiration from 
these sorts of resources, our focus on data-driven 
statistical models has led us to conceive of the 
platform as integrating both data and models in a 
single resource.  Knowledge-based systems built on 
the current literature or data repositories, such as 
Ingenuity, Nextbio, or Gene Atlas also offer some of 
the tools but are focused on helping users mine 
existing knowledge using predefined analyses, rather 
than letting scientists explore novel mathematical 
approaches.  We envision integrating results 
generated by platform scientists with a variety of these 
sorts of resources.  Other efforts contain elements of 
the workflow and reproducibility themes central to the 
Platform, notably Gene Pattern45,   Taverna46, or 
Galaxy47 and these sorts of workflow systems and tool 
collections could be linked to the platform.  Ultimately 
we believe that the combination of a repository of 
curated and readily usable data, along with tools for 
data manipulation and analysis, a workflow versioning 
system and forum for collaborative modeling provides 
significant attractive features for users of the Platform. 
The open architecture of the platform should also 
make it possible to link to tools developed by others 
and indeed the presence of a repository of 
standardized and curated data will make direct 
comparisons of these approaches more tractable48-52. 
As is natural for a project of this scope all the 
answers are not available at the start. It is possible 
that unforeseen modeling techniques will be 
developed that make obsolete the current state of the 
art methodologies. Indeed, this is our hope: that by 
opening up the data and current approaches more 
people will have ready access to them and out of this 
will come better models. Thus, the focus should be on 
enabling rather than competing, so that patients are 
the winners through access to better drugs. Perhaps 
the hardest challenges ahead do not relate to technical 
challenges but rather to sociological ones related to 
how we collaborate. Undoubtedly the incentives for 
broad data sharing will not work for everyone, but if we 
recognize the importance of this issue it can be solved 
over time as a community. Initially the drivers will be 
from the few who recognize the importance of this 
concept, backed up by policies from publishers and 
funders, but ultimately the drive for change will come 
from striking examples of what can be done with broad 
data access and crowdsourced analysis. 
In conclusion, we believe that the time is right to 
combine the power of social networking, in terms of 
sharing and working as distributed teams, with the 
needs and opportunities engendered by the genomics 
revolution and the desire to translate public and private 
investment into demonstrable human benefit. Indeed, 
we believe that the scale and complexity of the 
problem ahead of us dictates that we work together in 
transparent and reproducible ways, and that we share 
and reuse data, tools, and models.  
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